Artificial intelligence is transforming drug discovery across target identification, lead optimization, clinical trial design, and biomarker discovery. AlphaFold's protein structure prediction — which solved one of biology's greatest challenges — has been integrated into drug discovery workflows across the industry. Generative AI models are designing novel drug-like molecules with desired properties. Machine learning models are identifying patient populations most likely to respond to experimental therapies, reducing clinical trial size and duration. Every major biotechnology company has established AI drug discovery programs — through internal teams, acquisitions, or partnerships with dedicated AI drug discovery companies including Recursion, Exscientia, and Insilico Medicine.
This report provides significant competitor information, analysis, and insight critical to the development and implementation of effective marketing and R&D programs.
Topics Covered
• AlphaFold and Protein Structure Prediction
• Generative Chemistry
• Clinical Trial Optimization
• Biomarker Discovery
• AI Drug Discovery Company Landscape
• Leading Company AI Programs
• Regulatory Considerations for AI-Designed Drugs
• Competitive Landscape
Table of Contents
1. Executive Summary
2. Technology Landscape Overview
3. AlphaFold and Protein Structure Prediction
4. Generative Chemistry
5. Clinical Trial Optimization
6. Biomarker Discovery
7. AI Drug Discovery Company Landscape
8. Leading Company AI Programs
9. Regulatory Considerations for AI-Designed Drugs
10. Competitive Landscape
11. Competitive Landscape
12. Strategic Conclusions and Recommendations
13. Appendix
List of Tables
Table 1. Technology Overview and Key Data 2025
Table 2. AlphaFold and Protein Structure Prediction
Table 3. Generative Chemistry
Table 4. Clinical Trial Optimization
Table 5. Biomarker Discovery
Table 6. AI Drug Discovery Company Landscape
Table 7. Leading Company AI Programs
Table 8. Regulatory Considerations for AI-Designed Drugs
Table 9. Competitive Landscape
Table 10. Leading Companies — Technology Investment and Strategy 2025
Table 11. M&A and Partnership Activity 2023-2025
Table 12. Key Risks and Mitigation Strategies
Companies Profiled
Amgen
Gilead Sciences
Regeneron
Biogen
Vertex
BioNTech
Moderna
Genentech
CSL Behring
